Education

Ph.D. in Biomedical Sciences, Specialization in Health and Environmental Chemistry, Department of Chemistry, Oakland University, Rochester, MI, 2002

Current position

Assistant Professor in Pharmacology, Department of Pharmacology, Wayne State University School of Medicine, Detroit, MI

Publications

1. Sharma, R., Knoll, J. D., Martin, P. D., Podgorski, I., Turro, C. and Kodanko, J. J. (2014). Ruthenium Tris(2-pyridylmethyl)amine as an Effective Photocaging Group for Nitriles. Inorg Chem 53(7): 3272-3274.
   
2. Respondek, T., Sharma, R., Herroon, M. K., Garner, R. N., Knoll, J. D., Cueny, E., Turro, C., Podgorski, I. and Kodanko, J. J. (2014). Inhibition of Cathepsin Activity in a Cell-Based Assay by a Light-Activated Ruthenium Compound. ChemMedChem. (Epub ahead of print)
   
3. Hardaway, A. L., Herroon, M. K., Rajagurubandara, E. and Podgorski, I. (2014). Bone marrow fat: linking adipocyte-induced inflammation with skeletal metastases. Cancer Metastasis Rev.
   
4. Herroon, M. K., Rajagurubandara, E., Hardaway, A. L., Powell, K., Turchick, A., Feldmann, D. and Podgorski, I. (2013). Bone marrow adipocytes promote tumor growth in bone via FABP4-dependent mechanisms. Oncotarget 4(11): 2108-2123.
   
5. Hardaway, A. L. and Podgorski, I. (2013). IL-1beta, RAGE and FABP4: targeting the dynamic trio in metabolic inflammation and related pathologies. Future Med Chem 5(10): 1089-1108.
   
6. Herroon, M. K., Rajagurubandara, E., Rudy, D. L., Chalasani, A., Hardaway, A. L. and Podgorski, I. (2013). Macrophage cathepsin K promotes prostate tumor progression in bone. Oncogene 32(12): 1580-1593.
   
7. Respondek, T., Garner, R. N., Herroon, M. K., Podgorski, I., Turro, C. and Kodanko, J. J. (2011). Light activation of a cysteine protease inhibitor: caging of a peptidomimetic nitrile with Ru^II(bpy)₂. J Am Chem Soc 133(43): 17164-17167.
   
8. Podgorski, I. (2011). Inhibiting Cysteine Cathepsins in the Bone: New Functions and Off-Target Effects. Clinical Reviews in Bone and Mineral Metabolism 9(2): 81-82.
   
9. Trivedi, E. R., Harney, A. S., Olive, M. B., Podgorski, I., Moin, K., Sloane, B. F., Barrett, A. G., Meade, T. J. and Hoffman, B. M. (2010). Chiral porphyrazine near-IR optical imaging agent exhibiting preferential tumor accumulation. Proc Natl Acad Sci U S A 107(4): 1284-1288.
   
10. Jedeszko, C., Victor, B. C., Podgorski, I. and Sloane, B. F. (2009). Fibroblast hepatocyte growth factor promotes invasion of human mammary ductal carcinoma in situ. Cancer Res 69(23): 9148-9155.
    
11. Podgorski, I., Linebaugh, B. E., Koblinski, J. E., Rudy, D. L., Herroon, M. K., Olive, M. B. and Sloane, B. F. (2009). Bone marrow-derived cathepsin K cleaves SPARC in bone metastasis. Am J Pathol 175(3): 1255-1269.
    
12. Podgorski, I. (2009). Future of anticathepsin K drugs: dual therapy for skeletal disease and atherosclerosis? Future Med Chem 1(1): 21-34.
    
13. Podgorski, I., Linebaugh, B. E. and Sloane, B. F. (2007). Cathepsin K in the bone microenvironment: link between obesity and prostate cancer? Biochem Soc Trans 35(Pt 4): 701-703.
    
14. Podgorski, I. and Sloane, B. F. (2006). Loss of caspase-8 in tumor cells: mechanism to overcome integrin-mediated death? Mol Interv 6(3): 132-136.
    
15. Sloane, B. F., Sameni, M., Podgorski, I., Cavallo-Medved, D. and Moin, K. (2006). Functional imaging of tumor proteolysis. Annu Rev Pharmacol Toxicol 46: 301-315.
    
16. Sloane, B. F., Yan, S., Podgorski, I., Linebaugh, B. E., Cher, M. L., Mai, J., Cavallo-Medved, D., Sameni, M., Dosescu, J. and Moin, K. (2005). Cathepsin B and tumor proteolysis: contribution of the tumor microenvironment. Semin Cancer Biol 15(2): 149-157.
    
17. Podgorski, I., Linebaugh, B. E., Sameni, M., Jedeszko, C., Bhagat, S., Cher, M. L. and Sloane, B. F. (2005). Bone microenvironment modulates expression and activity of cathepsin B in prostate cancer. Neoplasia 7(3): 207-223.
    
18. Podgorski, I. and Sloane, B. F. (2003). Cathepsin B and its role(s) in cancer progression. Biochem Soc Symp(70): 263-276.
    
19. Podgorski, I. and Bull, A. W. (2001). Energy-dependent export of the 13-oxooctadecadienoic acid-glutathione conjugate from HT-29 cells and plasma membrane vesicles. Biochim Biophys Acta 1533(1): 55-65.
    
20. Blackburn, M. L., Podgorski, I. and Bull, A. W. (1999). Specific protein targets of 13-oxooctadecadienoic acid (13-OXO) and export of the 13-OXO-glutathione conjugate in HT-29 cells. Biochim Biophys Acta 1440(2-3): 225-234.